DO-BO

How can AI unlock the potential of Market Access, Sandip Shah?

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer discusses the transformative power of AI with industry veteran Sandip Shah. With over three decades in healthcare, Sandip shares his journey from sales rep to running Market Access Solutions, emphasizing on how AI is reshaping the landscape. 

Discover how AI is revolutionizing market research, streamlining dossier preparation, and reshaping pricing strategies. This episode is for anyone who wants to dive deep into how the potential of AI in enhancing market research through emotion recognition and data analysis can significantly impact payer research and training for sales reps. Imagine having comprehensive dossiers at your fingertips in the future, reducing preparation time from months to seconds.

Listen now to explore how AI is set to redefine market access, driving efficiency and innovation in ways we’ve only begun to imagine. Stay ahead of the curve and join the conversation on how AI will shape our industry’s future!

Related

This is a repost of a popular episode of MAP – Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data […]

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now. They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a […]

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, […]